InflammamiR-146a and -155 Plasma Levels are Associated with Clinical Efficacy of Risankizumab Treatment in Psoriatic Patients: Pilot Study
Federico Diotallevi(Marche Polytechnic University), Annamaria Offidani(Marche Polytechnic University)
Cited by 7
Related Papers
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*
|British Journal of Dermatology|2020|175
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study
|Journal of the European Academy of Dermatology and Venereology|2020|98
The mesenchymal stem cell profile in psoriasis
|British Journal of Dermatology|2011|82
Characterization and profiling of immunomodulatory genes in resident mesenchymal stem cells reflect the Th1-Th17/Th2 imbalance of psoriasis
|Archives of Dermatological Research|2014|76
Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis
|British Journal of Dermatology|2012|66